Raoul SantiagoM.D., M.Sc.

Raufaste-Cazavieille V, Santiago R, Droit A

Multi-omics analysis: Paving the path toward achieving precision medicine in cancer treatment and immuno-oncology

Front Mol Biosci, 9 , 2022.

Résumé | Liens:

Ilinca AP, Dakhallah N, Souza AM, Leclerc MÈ, Mezziani S, Brossard J, Vézina C, Santiago R, Pelland-Marcotte MC, Tran TH

Update: Clinical characteristics and outcomes of SARS-CoV-2 infection in pediatric oncology patients in the province of Quebec

Pediatr Blood Cancer, 2022.

| Liens:

Ilinca AP, Dakhallah N, Souza AM, Liu J, Bérubé S, Brossard J, Vézina C, Pelland-Marcotte MC, Santiago R, Tran TH

Clinical characteristics and outcomes of SARS-CoV-2 infection in pediatric oncology patients in the province of Quebec

Pediatr Blood Cancer, 69 (4), 2022.

| Liens:

Tran TH, Langlois S, Meloche C, Caron M, Saint-Onge P, Rouette A, Bataille AR, Jimenez-Cortes C, Sontag T, Bittencourt H, Laverdière C, Lavallée VP, Leclerc JM, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Michon B, Santiago R, Stevenson KE, Welch JJG, Schroeder KM, Koch V, Cellot S, Silverman LB, Sinnett D

Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001

Blood Adv, 6 (4), 2022.

Résumé | Liens:

Santiago R, Tran TH

Genomics and precision medicine in pediatric acute lymphoblastic leukemia

J Transl Genet Genom, 5 , 2021.

Résumé | Liens:

Pincez T, Santiago R, Bittencourt H, Louis I, Bilodeau M, Rouette A, Jouan L, Landry JR, Couture F, Richer J, Teira P, Duval M, Cellot S

Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children

Bone Marrow Transplant, 56 (12), 2021.

Résumé | Liens:

Santiago R, Ortiz Jimenez J, Forghani R, Muthukrishnan N, Del Corpo O, Karthigesu S, Haider MY, Reinhold C, Assouline S

CT-based radiomics model with machine learning for predicting primary treatment failure in diffuse large B-cell Lymphoma

Transl Oncol, 14 (10), 2021.

Résumé | Liens:

Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David KA, Wei C, Lansigan F, Emery L, Persky D, Smith SM, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, Armand P

Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma

Oncologist, 25 (6), 2020.

Résumé | Liens:

Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C

Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy

Br J Haematol, 191 (1), 2020.

Résumé | Liens:

Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel AB, Diefenbach C

Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy

Oncologist, 25 (10), 2020.

Résumé | Liens: